R&D | February 11, 2026
The company has commissioned a new plant at Khanna (Punjab), which has begun commercial production
Anand Chemiceutics serves over 1,500 laboratories, hospitals, and government institutions
Revenue from operations surged 30% year-on-year to Rs. 68,645 million
Launched in August 2025, GSK India’s Oncology business is rapidly gaining momentum
The revenues this quarter are in line with the outlook we envisaged for the year
The unveiling marks Time Medical India’s entry into next-generation helium-free MRI technology
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
Pfizer’s anti-infectives portfolio includes both established therapies for moderate to severe infections and newer, clinically robust antimicrobial treatments
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Stalevo Tablets
Subscribe To Our Newsletter & Stay Updated
